Details of the Drug

General Information of Drug (ID: DMAYL0T)

Drug Name
Phenylbutazone
Synonyms
Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione
Indication
Disease Entry ICD 11 Status REF
Chronic pain MG30 Approved [1]
Therapeutic Class
Analgesics
Affected Organisms
Humans and other mammals
ATC Code
M01AA01: Phenylbutazone
M01AA: Butylpyrazolidines
M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M: MUSCULO-SKELETAL SYSTEM
M01AA01: Phenylbutazone
M01AA: Butylpyrazolidines
M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M: MUSCULO-SKELETAL SYSTEM
M01AA01: Phenylbutazone
M01AA: Butylpyrazolidines
M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M: MUSCULO-SKELETAL SYSTEM
: Phenylbutazone
M01CX: Other specific antirheumatic agents
M01C: SPECIFIC ANTIRHEUMATIC AGENTS
M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M: MUSCULO-SKELETAL SYSTEM
M02AA01: Phenylbutazone
M02AA: Antiinflammatory preparations, non-steroids for topical use
M02A: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M: MUSCULO-SKELETAL SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 308.4
Logarithm of the Partition Coefficient (xlogp) 3.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [3]
Elimination
1% of drug is excreted from urine in the unchanged form [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 32.42716 micromolar/kg/day [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.7 mg/mL [2]
Chemical Identifiers
Formula
C19H20N2O2
IUPAC Name
4-butyl-1,2-diphenylpyrazolidine-3,5-dione
Canonical SMILES
CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3
InChIKey
VYMDGNCVAMGZFE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4781
ChEBI ID
CHEBI:48574
CAS Number
50-33-9
UNII
GN5P7K3T8S
DrugBank ID
DB00812
TTD ID
D07VHR
VARIDT ID
DR00560
INTEDE ID
DR1281

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [6]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [8]
L-selectin (SELL) OT6RAJZR LYAM1_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic pain
ICD Disease Classification MG30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Phenylbutazone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Phenylbutazone and Levomilnacipran. Chronic pain [MG30] [10]
Coadministration of a Drug Treating the Disease Different from Phenylbutazone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Phenylbutazone and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [11]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Phenylbutazone and Repaglinide. Acute diabete complication [5A2Y] [12]
Glibenclamide DM8JXPZ Moderate Decreased renal excretion of Phenylbutazone caused by Glibenclamide. Acute diabete complication [5A2Y] [13]
Tolazamide DMIHRNA Moderate Decreased renal excretion of Phenylbutazone caused by Tolazamide. Acute diabete complication [5A2Y] [14]
Glipizide DMZA5PQ Moderate Decreased metabolism of Phenylbutazone caused by Glipizide. Acute diabete complication [5A2Y] [13]
Midostaurin DMI6E0R Moderate Increased metabolism of Phenylbutazone caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMTI0ZO Moderate Increased metabolism of Phenylbutazone caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Donepezil DMIYG7Z Moderate Increased metabolism of Phenylbutazone caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [17]
Dronedarone DMA8FS5 Moderate Increased metabolism of Phenylbutazone caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Phenylbutazone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Phenylbutazone and Cilostazol. Arterial occlusive disease [BD40] [20]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Phenylbutazone and Budesonide. Asthma [CA23] [21]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Phenylbutazone and Ofloxacin. Bacterial infection [1A00-1C4Z] [22]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Phenylbutazone and Kanamycin. Bacterial infection [1A00-1C4Z] [23]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Phenylbutazone and Streptomycin. Bacterial infection [1A00-1C4Z] [23]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Phenylbutazone and Gemifloxacin. Bacterial infection [1A00-1C4Z] [22]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Phenylbutazone and Norfloxacin. Bacterial infection [1A00-1C4Z] [24]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Phenylbutazone and ABT-492. Bacterial infection [1A00-1C4Z] [22]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Phenylbutazone and Levofloxacin. Bacterial infection [1A00-1C4Z] [22]
Telithromycin DMZ4P3A Moderate Increased metabolism of Phenylbutazone caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Cariprazine DMJYDVK Moderate Increased metabolism of Phenylbutazone caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [13]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Phenylbutazone and Etidronic acid. Bone paget disease [FB85] [26]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Phenylbutazone and Risedronate. Bone paget disease [FB85] [26]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Phenylbutazone and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [27]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Phenylbutazone caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Lapatinib DM3BH1Y Moderate Increased metabolism of Phenylbutazone caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
LY2835219 DM93VBZ Moderate Increased metabolism of Phenylbutazone caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Exemestane DM9HPW3 Moderate Increased metabolism of Phenylbutazone caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Phenylbutazone caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Tucatinib DMBESUA Moderate Increased metabolism of Phenylbutazone caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Palbociclib DMD7L94 Moderate Increased metabolism of Phenylbutazone caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
Alpelisib DMEXMYK Moderate Increased metabolism of Phenylbutazone caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Phenylbutazone caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Bosutinib DMTI8YE Moderate Increased metabolism of Phenylbutazone caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Phenylbutazone and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [20]
Atorvastatin DMF28YC Moderate Increased metabolism of Phenylbutazone caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [35]
Macitentan DMP79A1 Moderate Increased metabolism of Phenylbutazone caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [36]
PF-04449913 DMSB068 Moderate Increased metabolism of Phenylbutazone caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [37]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Phenylbutazone and Regorafenib. Colorectal cancer [2B91] [13]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Phenylbutazone and Drospirenone. Contraceptive management [QA21] [38]
Ulipristal DMBNI20 Moderate Increased metabolism of Phenylbutazone caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [13]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Phenylbutazone and Ardeparin. Coronary thrombosis [BA43] [39]
Mifepristone DMGZQEF Moderate Increased metabolism of Phenylbutazone caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [40]
Osilodrostat DMIJC9X Moderate Increased metabolism of Phenylbutazone caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [25]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Phenylbutazone and Rivaroxaban. Deep vein thrombosis [BD71] [41]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Phenylbutazone and Vilazodone. Depression [6A70-6A7Z] [10]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Phenylbutazone and Vortioxetine. Depression [6A70-6A7Z] [10]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Phenylbutazone and Milnacipran. Depression [6A70-6A7Z] [10]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Phenylbutazone and Escitalopram. Depression [6A70-6A7Z] [10]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Phenylbutazone and Desvenlafaxine. Depression [6A70-6A7Z] [10]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Phenylbutazone caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [42]
Zonisamide DM0DTF7 Moderate Increased metabolism of Phenylbutazone caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Phenylbutazone and Cannabidiol. Epileptic encephalopathy [8A62] [13]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Phenylbutazone when combined with Ethacrynic acid. Essential hypertension [BA00] [44]
Praziquantel DMOU1PK Moderate Increased metabolism of Phenylbutazone caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [45]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Phenylbutazone caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [46]
Tazemetostat DMWP1BH Moderate Increased metabolism of Phenylbutazone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [47]
Solifenacin DMG592Q Moderate Increased metabolism of Phenylbutazone caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [48]
Mirabegron DMS1GYT Minor Increased metabolism of Phenylbutazone caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [49]
Ripretinib DM958QB Moderate Increased metabolism of Phenylbutazone caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [11]
Sunitinib DMCBJSR Moderate Increased metabolism of Phenylbutazone caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [11]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Phenylbutazone and Avapritinib. Gastrointestinal stromal tumour [2B5B] [13]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Phenylbutazone when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [44]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Phenylbutazone when combined with Bumetanide. Heart failure [BD10-BD1Z] [44]
MK-1439 DM215WE Moderate Increased metabolism of Phenylbutazone caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Phenylbutazone caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Fostemsavir DM50ILT Minor Increased metabolism of Phenylbutazone caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Tipranavir DM8HJX6 Moderate Increased metabolism of Phenylbutazone caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Dolutegravir DMCZGRE Minor Increased metabolism of Phenylbutazone caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Saquinavir DMG814N Moderate Increased metabolism of Phenylbutazone caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Etravirine DMGV8QU Moderate Increased metabolism of Phenylbutazone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Phenylbutazone caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Darunavir DMN3GCH Moderate Increased metabolism of Phenylbutazone caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Atazanavir DMSYRBX Moderate Increased metabolism of Phenylbutazone caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Maraviroc DMTL94F Moderate Increased metabolism of Phenylbutazone caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Phenylbutazone and Mipomersen. Hyper-lipoproteinaemia [5C80] [54]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Phenylbutazone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [55]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Phenylbutazone and BMS-201038. Hyper-lipoproteinaemia [5C80] [56]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Phenylbutazone and Dipyridamole. Hypertension [BA00-BA04] [20]
Tolvaptan DMIWFRL Moderate Increased metabolism of Phenylbutazone caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [13]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Phenylbutazone and Balsalazide. Indeterminate colitis [DD72] [57]
Suvorexant DM0E6S3 Moderate Increased metabolism of Phenylbutazone caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [58]
Ramelteon DM7IW9J Moderate Increased metabolism of Phenylbutazone caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [59]
Zaleplon DMGFWSM Minor Increased metabolism of Phenylbutazone caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [60]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Phenylbutazone caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [61]
Naloxegol DML0B41 Moderate Increased metabolism of Phenylbutazone caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [62]
Pemigatinib DM819JF Moderate Increased metabolism of Phenylbutazone caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [63]
Crizotinib DM4F29C Moderate Increased metabolism of Phenylbutazone caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [64]
Brigatinib DM7W94S Moderate Increased metabolism of Phenylbutazone caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [11]
Ceritinib DMB920Z Moderate Increased metabolism of Phenylbutazone caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [65]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Phenylbutazone caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [66]
Osimertinib DMRJLAT Moderate Increased metabolism of Phenylbutazone caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [67]
Capmatinib DMYCXKL Moderate Increased metabolism of Phenylbutazone caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [68]
Selpercatinib DMZR15V Moderate Increased metabolism of Phenylbutazone caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [25]
Artemether DM48QOT Moderate Increased metabolism of Phenylbutazone caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [11]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Phenylbutazone and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [69]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Phenylbutazone and Idelalisib. Mature B-cell leukaemia [2A82] [70]
GDC-0199 DMH0QKA Moderate Increased metabolism of Phenylbutazone caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [71]
IPI-145 DMWA24P Moderate Increased metabolism of Phenylbutazone caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [72]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Phenylbutazone and Acalabrutinib. Mature B-cell lymphoma [2A85] [73]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Phenylbutazone and Ibrutinib. Mature B-cell lymphoma [2A85] [74]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Phenylbutazone and Ponatinib. Mature B-cell lymphoma [2A85] [75]
Vemurafenib DM62UG5 Moderate Increased metabolism of Phenylbutazone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [76]
Selumetinib DMC7W6R Moderate Increased metabolism of Phenylbutazone caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [77]
LGX818 DMNQXV8 Moderate Increased metabolism of Phenylbutazone caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [78]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Phenylbutazone and Exjade. Mineral absorption/transport disorder [5C64] [79]
Panobinostat DM58WKG Moderate Increased metabolism of Phenylbutazone caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [80]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Phenylbutazone and Ocrelizumab. Multiple sclerosis [8A40] [81]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Phenylbutazone and Deflazacort. Muscular dystrophy [8C70] [21]
Nilotinib DM7HXWT Moderate Increased metabolism of Phenylbutazone caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [82]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Phenylbutazone and Ruxolitinib. Myeloproliferative neoplasm [2A20] [20]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Phenylbutazone and Dasatinib. Myeloproliferative neoplasm [2A20] [83]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Phenylbutazone and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [84]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Phenylbutazone and Prasugrel. Myocardial infarction [BA41-BA43] [13]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Phenylbutazone and Vorapaxar. Myocardial infarction [BA41-BA43] [85]
Rolapitant DM8XP26 Moderate Increased metabolism of Phenylbutazone caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [86]
Entrectinib DMMPTLH Moderate Increased metabolism of Phenylbutazone caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [13]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Phenylbutazone and Sibutramine. Obesity [5B80-5B81] [87]
Polythiazide DMCH80F Moderate Antagonize the effect of Phenylbutazone when combined with Polythiazide. Oedema [MG29] [44]
Olaparib DM8QB1D Moderate Increased metabolism of Phenylbutazone caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [11]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Phenylbutazone and MK-4827. Ovarian cancer [2C73] [13]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Phenylbutazone and Aspirin. Pain [MG30-MG3Z] [88]
Buprenorphine DMPRI8G Moderate Increased metabolism of Phenylbutazone caused by Buprenorphine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [89]
Hydrocodone DMQ2JO5 Moderate Increased metabolism of Phenylbutazone caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [90]
Pimavanserin DMR7IVC Moderate Increased metabolism of Phenylbutazone caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [91]
Lefamulin DME6G97 Moderate Increased metabolism of Phenylbutazone caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [92]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Phenylbutazone caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [93]
Enzalutamide DMGL19D Moderate Increased metabolism of Phenylbutazone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [94]
Darolutamide DMV7YFT Moderate Increased metabolism of Phenylbutazone caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [95]
Silodosin DMJSBT6 Moderate Increased metabolism of Phenylbutazone caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [11]
Apremilast DMTWS9E Moderate Increased metabolism of Phenylbutazone caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [96]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Phenylbutazone and Iloprost. Pulmonary hypertension [BB01] [97]
Riociguat DMXBLMP Moderate Increased metabolism of Phenylbutazone caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [98]
Axitinib DMGVH6N Moderate Increased metabolism of Phenylbutazone caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [99]
Temsirolimus DMS104F Moderate Increased metabolism of Phenylbutazone caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [11]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Phenylbutazone and Gatifloxacin. Respiratory infection [CA07-CA4Z] [24]
Tofacitinib DMBS370 Moderate Increased metabolism of Phenylbutazone caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [11]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Phenylbutazone and Dexamethasone. Rheumatoid arthritis [FA20] [21]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Phenylbutazone and Leflunomide. Rheumatoid arthritis [FA20] [55]
Quetiapine DM1N62C Moderate Increased metabolism of Phenylbutazone caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [11]
Aripiprazole DM3NUMH Moderate Increased metabolism of Phenylbutazone caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [100]
Fentanyl DM8WAHT Moderate Increased metabolism of Phenylbutazone caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [90]
Avanafil DM75CXN Moderate Increased metabolism of Phenylbutazone caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [101]
Tadalafil DMJZHT1 Moderate Increased metabolism of Phenylbutazone caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [13]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Phenylbutazone caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [102]
LDE225 DMM9F25 Moderate Increased metabolism of Phenylbutazone caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [103]
Larotrectinib DM26CQR Moderate Increased metabolism of Phenylbutazone caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Phenylbutazone and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [21]
Docetaxel DMDI269 Moderate Increased metabolism of Phenylbutazone caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [104]
Trabectedin DMG3Y89 Moderate Increased metabolism of Phenylbutazone caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
Armodafinil DMGB035 Moderate Increased metabolism of Phenylbutazone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [105]
LEE011 DMMX75K Moderate Increased metabolism of Phenylbutazone caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
Taxol DMUOT9V Moderate Increased metabolism of Phenylbutazone caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [106]
Doxorubicin DMVP5YE Moderate Increased metabolism of Phenylbutazone caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Phenylbutazone and Pitolisant. Somnolence [MG42] [13]
Fostamatinib DM6AUHV Moderate Increased metabolism of Phenylbutazone caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [25]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Phenylbutazone and Caplacizumab. Thrombocytopenia [3B64] [20]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Phenylbutazone and Apixaban. Thrombosis [DB61-GB90] [13]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Phenylbutazone and Cangrelor. Thrombosis [DB61-GB90] [20]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Phenylbutazone and Brilinta. Thrombosis [DB61-GB90] [13]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Phenylbutazone and Cabozantinib. Thyroid cancer [2D10] [107]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Phenylbutazone and Sirolimus. Transplant rejection [NE84] [108]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Phenylbutazone and Tacrolimus. Transplant rejection [NE84] [108]
Tolbutamide DM02AWV Moderate Decreased renal excretion of Phenylbutazone caused by Tolbutamide. Type 2 diabetes mellitus [5A11] [14]
Saxagliptin DMGXENV Moderate Increased metabolism of Phenylbutazone caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [109]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Phenylbutazone and Olsalazine. Ulcerative colitis [DD71] [57]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Phenylbutazone and Plazomicin. Urinary tract infection [GC08] [110]
Elagolix DMB2C0E Moderate Increased metabolism of Phenylbutazone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [111]
Ganciclovir DM1MBYQ Moderate Increased risk of nephrotoxicity by the combination of Phenylbutazone and Ganciclovir. Virus infection [1A24-1D9Z] [11]
Valganciclovir DMS2IUH Moderate Increased risk of nephrotoxicity by the combination of Phenylbutazone and Valganciclovir. Virus infection [1A24-1D9Z] [11]
⏷ Show the Full List of 170 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7270).
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.
6 Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos. 2001 May;29(5):701-11.
7 Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys. 2006 Oct 1;454(1):72-9.
8 A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica. 1999 Mar;29(3):269-79.
9 Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem. 2002 Oct 11;277(41):38212-21. doi: 10.1074/jbc.M205142200. Epub 2002 Jul 29.
10 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
11 Cerner Multum, Inc. "Australian Product Information.".
12 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
13 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14 Mahfouz M, Abdel-Maguid R, El-Dakhakhny M "Potentiation of the hypoglycaemic action of tolbutamide by different drugs." Arzneimittelforschung 20 (1970): 120-2. [PMID: 5467602]
15 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
16 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
17 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
18 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
21 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
22 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
23 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
24 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
25 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
26 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
27 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
28 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
29 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
30 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
31 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
32 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
33 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
34 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
36 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
37 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
39 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
40 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
41 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
42 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
43 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
44 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
45 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
46 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
47 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
48 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
49 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
50 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
51 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
52 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
53 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
54 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
55 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
56 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
57 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
58 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
59 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
60 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
61 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
62 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
63 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
64 Cerner Multum, Inc. "Canadian Product Information.".
65 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
66 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
67 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
68 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
69 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
70 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
71 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
72 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
73 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
74 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
75 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
76 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
77 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
78 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
79 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
80 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
81 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
82 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
83 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
84 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
85 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
86 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
87 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
88 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
89 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
90 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
91 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
92 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
93 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
94 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
95 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
96 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
97 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
98 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
99 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
100 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
101 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
102 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
103 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
104 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
105 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
106 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
107 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
108 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
109 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
110 Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
111 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.